02:10 , Oct 20, 2018 |  BioCentury  |  Product Development

CVOT damage in diabetes

As FDA reconsiders its requirement for cardiovascular outcomes trials of new diabetes candidates, it’s clear that the development of new therapies has slowed since it was implemented. In December 2008, FDA issued guidance requiring diabetes...
19:58 , Sep 21, 2017 |  BC Innovations  |  Targets & Mechanisms

Appetite for GFRAL

Simultaneous publications from Eli Lilly and Co ., Johnson & Johnson and Novo Nordisk A/S identifying GFRAL as the receptor of the anti-obesity hormone GDF15 will undoubtedly accelerate therapeutic translation of the pathway. The race...
19:39 , Jun 23, 2017 |  BC Week In Review  |  Company News

KeyBioscience grants Lilly rights to Type II diabetes platform

The KeyBioscience AG subsidiary of Nordic Bioscience A/S (Herlev, Denmark) granted Eli Lilly and Co. (NYSE:LLY) worldwide rights to develop and commercialize its Dual Amylin Calcitonin Receptor Agonist (DACRA) platform to develop compounds to treat...
07:00 , Aug 20, 2012 |  BC Week In Review  |  Company News

Unigene musculoskeletal news

Unigene said in its 2Q12 earnings that it will need to obtain "significant" funding to continue operations, address its debt and restructure its balance sheet. The company also noted that it was "unlikely" that Victory...
07:00 , Aug 8, 2011 |  BC Week In Review  |  Clinical News

Pramlintide/Metreleptin: Development discontinued

Amylin and partner Takeda discontinued development of pramlintide/metreleptin after a commercial reassessment of the obesity candidate. The companies said they would continue to evaluate other assets as potential obesity treatments under their 2009 deal. In...
07:00 , Jul 18, 2011 |  BC Week In Review  |  Clinical News

Unigene preclinical data

In rats, once-daily 5 and 20 µg/kg UGP281 significantly reduced mean food intake from baseline by 55% and 84%, respectively. Additionally, low- and high-dose UGP281 led to sustained weight loss relative to placebo at day...
07:00 , Mar 21, 2011 |  BC Week In Review  |  Clinical News

Pramlintide/metreleptin: Phase II halted

Amylin and partner Takeda suspended a double-blind, placebo-controlled, U.S. Phase II trial of pramlintide/metreleptin to treat obesity after 2 patients in a previously completed study developed "antibody-related" responses to metreleptin. According to Amylin, a potential...
08:00 , Feb 17, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine disease

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Endocrine disease Obesity Low-density lipoprotein-related protein 1 a-2-macroglobulin receptor (LRP1; CD91); leptin receptor (LEPR; CD295) Studies in cell culture and in mice suggest that LRP1...
07:00 , Jul 12, 2010 |  BC Week In Review  |  Clinical News

Symlin pramlintide acetate: Post-marketing study data

Amylin Pharmaceuticals Inc. (NASDAQ:AMLN), San Diego, Calif.   Product: Symlin pramlintide acetate   Business: Endocrine   Molecular target: Amylin receptor   Description: Synthetic amylin analog   Indication: Treat Type II diabetes   Endpoint: Occurrence of...
08:00 , Mar 1, 2010 |  BC Week In Review  |  Clinical News

Pramlintide/Metreleptin: Extension study data

Data from a 24-week extension of a 28-week Phase II trial in about 275 patients showed that patients who continued treatment with pramlintide/metreleptin for a total of 52 weeks demonstrated sustained weight loss compared to...